Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

F. Lordick,Sylvie Lorenzen,Salah-Eddin Al-Batran,Ralf-Dieter Hofheinz,Peter C. Thuss-Patience,R. Porschen,N. Rothling,Tibor Schuster,Christian Peschel,Arbeitsgemeinschaft Internistische Onkologie

Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

2008

F. Lordick
Sylvie Lorenzen
Salah-Eddin Al-Batran
Ralf-Dieter Hofheinz
Peter C. Thuss-Patience
R. Porschen
N. Rothling
Tibor Schuster
Christian Peschel
Arbeitsgemeinschaft Internistische Onkologie

4546 Background: Combining the EGFR antibody cetuximab with chemotherapy has shown increased efficacy compared with chemotherapy alone in various types of cancer. This trial was conducted to assess...

Keywords:

Carcinoma
Cetuximab
Pathology
Esophagus
Cisplatin
Internal medicine
Cancer research
Oncology
Medicine
Phases of clinical research
first line
Cancer
Chemotherapy
EGFR Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations